02005nas a2200169   4500000000100000008004100001260001200042653009500054100001300149700001200162700001400174700001500188700001300203245009300216520151200309022001401821       2023                            d  c02/202310aPharmaceutical Technology. Routes of Drug Administration. Dapsone. Clofazimine. Rifampicin1 aSantos J1 aAlves F1 aJúnior E1 aSobrinho J1 aSoares M00aEvolution of pediatric pharmaceutical forms for treatment of Hansen's disease (leprosy).3 a<p><strong>INTRODUCTION: </strong>Leprosy is a neglected, infectious, granulomatous and chronic disease caused by the pathological agent . The course of the disease is more aggressive in patients under 15 years of age, but the current treatment offered worldwide consists of solid forms, by the combination of antibiotics such as rifampicin, clofazimine and dapsone. This represents results in lack of adherence in pediatric patients and drug therapy failure, although numerous formulations and technologies have already been developed.</p>

<p><strong>AREA COVERED: </strong>This study aims to analyze the technological evolution of the pharmaceutical treatment of leprosy, aimed at children. A review of patents around the world was conducted to look for technical and clinical aspects of formulations and devices.</p>

<p><strong>EXPERT OPINION: </strong>Innovative formulations for pediatric patients were classified according to the routes of administration as oral, inhalable, injectable and transdermal. The formulations were also organized as alternatives for pediatric therapy, taking into account the physicochemical aspects of drugs and the physiological aspects of pediatric patients. Among the difficulties for the patented formulations to reach the market, of special note is the low stability of the physicochemical characteristics of the drugs. Optimization of formulations would favor the pediatric treatment of leprosy, aiming at therapeutic success and improved quality of life.</p>
  a1744-7674